Endo Pharma pulls out of axomadol deal with Grunenthal
USA-based Endo Pharmaceuticals (Nasdaq: ENDP) says that it is terminating its research program and collaboration with independent German drugmaker Grunenthal related to the development of axomadol.
Endo licensed exclusive rights to develop and market axomadol in the USA and Canada from Grunenthal over two years ago, when the drug was in Phase II development for the treatment of moderate-to-moderately severe chronic pain and diabetic peripheral neuropathic pain. (The Pharma Letter March 16, 2009).
"As a leader in the field of pain management, Endo remains committed to the development and commercialization of pain therapeutics," said Ivan Gergel, executive vice president, R&D, at Endo, adding: "We have appreciated the opportunity to collaborate with Grunenthal on this program and they have been an excellent partner."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze